Status In progress
Process STA
ID number 894

Project Team

Project lead Stephanie Callaghan

Email enquiries


Companies sponsors Novartis (midostaurin)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Leukaemia CARE
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated guideline groups None
Associated public health groups None
Comparator companies None
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
21 March 2018 Committee meeting: 3
14 March 2018 New analyses have been received and will be reviewed by the committee at a meeting on Wednesday 21 March 2018. There will be a short discussion in public (part 1) to consider the suspended FAD in relation to the updated value proposition before the committee continue their decision making in private (part 2).
08 March 2018 Following release of the FAD, the company, Novartis has requested to submit an updated value proposition for midostaurin. While we consider whether this value proposition can be put forward to the appraisal committee, NICE has suspended the FAD for consideration for appeal and will not publish the FAD on the NICE website.
23 January 2018 Committee meeting: 2
05 December 2017 - 04 January 2018 Appraisal consultation: 1
09 November 2017 Committee meeting: 1
25 May 2017 This appraisal has formally started and was planned to be discussed by the NICE appraisal committee on Wednesday 14 June 2017. However this has been rescheduled and the topic will now be appraised on Thursday 9 November 2017.
05 January 2017 Invitation to participate
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance